Brought to you by:
Grasping the nettle: The need to tackle PAD problem head on is huge, says 2024 Veith lecturer
Huge opportunities abound for vascular surgeons to take a leadership role on the frontlines of a developing peripheral arterial disease (PAD) treatment crisis in the U.S., says Michael Conte, MD, who gave the second annual Frank J. Veith Distinguished Lecture…
A calling seeded in childhood: Uniting vascular surgery for the betterment of patient care
Many attending the 2024 Vascular Annual Meeting (VAM; June 19–22) might have been unaware of the early life of 2023–24 Society for Vascular Surgery (SVS) President Joseph Mills, MD. Amongst an intrepid childhood following his father’s career as a dentist,…
The top 10 most popular Vascular Specialist stories of June 2024
In June, the most read stories from Vascular Specialist included key reports from the 2024 Vascular Annual Meeting (VAM; June 19–22) covering TEVAR, CEA vs TCAR, PAD and CFA-reintervention, among others; Linda Harris’ placement as SVS vice president; the relationship…
Sonovein FDA pivotal study treatments completed: Theraclion reaches key milestone on schedule
Theraclion, a French MedTech company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, announces today that treatments in the Food and Drug Administration (FDA) pivotal study for Sonovein, an extracorporeal medical device made to treat varicose veins using…
Humacyte’s ATEV granted FDA Regenerative Medicine Advanced Therapy designation for advanced PAD
Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its investigational acellular tissue engineered vessel (ATEV), designed to treat patients with advanced peripheral arterial disease (PAD). This…
Smoking cessation remains a ‘ripe target’ for improved medication adherence in carotid disease
New data presented at the 2024 Vascular Annual Meeting (VAM) held June 19–22 in Chicago have revealed poor overall rates of medical therapy adherence in moderate asymptomatic carotid stenosis patients—with smoking cessation representing a “ripe target” for improvement moving forward.…
SVS raises alarm over healthcare consolidation in comments to FTC, DOJ, HHS
The Society for Vascular Surgery (SVS) has submitted comments to the Federal Trade Commission (FTC), the Department of Justice (DOJ) and the Department of Health and Human Services (HHS) in response to a Request for Information (RFI) concerning the consolidation…
Incentives and coaching offer promise for improving supervised exercise therapy completion in claudicants
Study findings were presented during Saturday, June 22’s Plenary Session 7 support current vascular guidelines advocating for effective supervised exercise therapy (SET) prior to offering vascular intervention for patients with intermittent claudication. That is the belief of Colin Cleary, PhD,…
Gore announces first commercial implant of Gore Tag thoracic branch endoprosthesis in Canada
Gore has announced the first commercial use of the Gore Tag thoracic branch endoprosthesis (TBE) in Canada. The news came as Canadian government health authority Health Canada approved the first-of-its-kind endovascular device, which is indicated to treat lesions of the…
VAM 2024: Paper exploring stroke rates in arch TEVAR emerges as winner of Poster Competition
The 2024 Vascular Annual Meeting (VAM) in Chicago showcased emerging talent in vascular surgery through a moderated Poster Competition held over two days of the conference. This event provided a platform for research and recognized excellence among the next generation…